Addiction ProfessionalDelaware Launches Fentanyl-Xylazine Combo Testing Strip Pilot

The strips deliver results within 5 minutes, applicable to various substances like powders, pills, and residues from bags or cookers.

Delaware is leading the nation with a groundbreaking initiative to combat its drug overdose problem, launching a pilot program this week for the use of combined fentanyl-xylazine testing strips, a product of SIVAD Diagnostic Medical Group.

Key Points:

• The pilot program has introduced the use of combination fentanyl-xylazine testing strips, named HarmGuard FX, developed by SIVAD Diagnostic Medical Group.
• HarmGuard FX strips can identify both fentanyl and xylazine, substances declared an emerging drug threat by the Office of National Drug Control Policy (ONDCP) in April.

Additional Points:

• The HarmGuard FX strips are part of SIVAD’s Harm Stopper Program, providing resources for different stakeholders and a cloud-based portal offering educational resources and information at a national level.
• The program employs geolocation services to provide users with access to local resources in participating states, such as nearby naloxone distribution locations, needle exchanges, counseling, and emergency services.
• Delaware has the third-highest drug overdose death rate per capita in the country, per CDC data.

Conclusion:

• SIVAD’s innovative drug testing strips are being deployed in Delaware with the aim of combating the escalating overdose crisis. The success of this pilot program could pave the way for similar initiatives nationwide.

Psychiatry Latest Posts

• 5 Trends That Will Determine The Hospital From The Future
• FDA Approves Lumicell’s Breast Cancer Imaging Tool
• Physician Practices Struggle After Change Healthcare Cyberattack: Unpaid Claims, Staff Strain, and Potential Closures
• Artificial Intelligence in Medicine
• Patients Deem AI-based ChatGPT More Empathetic than Neurologists